Hello, you're about to listen to a BBC podcast, and I'm Ed Gamble, host of another BBC podcast,

The Traitors Uncloaked. But my show is available only on BBC Sounds, just like Ellis and John's

Saturday bonus episodes, the Pop Top Ten podcast with Scott Mills and Ryland, and comedy specials

from the likes of Harriet Kemsley, Susie Ruffel and Rommas Shranger Nathan. However, and maybe I'm biased, it's really all about the traitors uncloked.

So for a whole bunch of exclusive scoops and podcasts, listen only on BBC Sounds.

This is the BBC.

Hello, coming up in the next half hour,

The Fry and Turnbull Effect, Margaret McCartney,

shares her thoughts on the impact of celebrities going public about their cancers

and pioneering new research into hip fractures that hopes to improve the quality of life after surgery.

But first, should the NHS pull the plug on the only drug treatments for dementia?

In a world first, the French Health Authority already has, after concluding that the dangers

of side effects outweigh any benefits. The delisting means the cost of four drugs,

denepazil, rivestigmine, gal Galantamine, and Mamantine is not reimbursable

under the French healthcare system. That's the equivalent of something no longer being

prescribable on the NHS. A similar move here would affect at least 400,000 people with

dementia currently on one of the drugs. Christoph Kopp is a GP in France, an editor of the Independent Medical Journal, Présquire,

which has long been expressing concerns.

There was big hopes at the start when these drugs came onto the market in the mid-90s.

But over time, we got more and more information about adverse effects

so that the journal Prescrier in 2012 concluded

that these drugs were more dangerous than helpful.

...